Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse

JAMA Oncology
Mohamed A Kharfan-DabajaMohamad Mohty

Abstract

The optimal treatment approach to patients with acute myeloid leukemia (AML) who relapse after an allogeneic hematopoietic cell transplant (allo-HCT) remains elusive. No randomized clinical trial comparing survival outcomes of a second allo-HCT (allo-HCT2) vs donor lymphocyte infusion (DLI) has been conducted to date. To compare overall survival (OS) after an allo-HCT2 or DLI in relapsed AML after a first allo-HCT. A retrospective registry study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation involving 418 adults who received an allo-HCT2 (n = 137) or DLI (n = 281) for postallograft-relapsed AML. Analysis was assessed on the principle of intent-to-first received intervention. The data were collected from November 21, 2015, to May 15, 2017, and analysis was performed June 1, 2017. Number of patients with relapsed AML who are alive after 2 years and 5 years from receiving an allo-HCT2 or DLI. Of the 418 patients, 228 (54.5%) were men; mean age was 46.2 years (interquartile range, 36.5-56.9 years). There was no apparent difference in OS whether an allo-HCT2 or DLI was prescribed (2-year OS with allo-HCT2, 26%; 5-year OS with allo-HCT2, 19%; 2-year OS with DLI, 25%; 5-year OS with ...Continue Reading

References

Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea BacigalupoMary Horowitz
Jun 19, 2010·The Lancet Oncology·Mary EapenUNKNOWN National Cord Blood Program of the New York Blood Center
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michel DuvalDaniel Weisdorf
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maximilian ChristopeitChristoph Schmid
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Apr 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart L ScottMitchell E Horwitz
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner

❮ Previous
Next ❯

Citations

Jan 11, 2019·Leukemia & Lymphoma·Hongbing MaYuping Gong
May 18, 2019·American Society of Clinical Oncology Educational Book·Michael HeuserJessica K Altman
Aug 15, 2019·European Journal of Haematology·Greta de JongMette D Hazenberg
Jun 5, 2019·Bone Marrow Transplantation·Nour M Moukalled, Mohamed A Kharfan-Dabaja
Feb 6, 2020·American Journal of Hematology·Cole Sterling, Jonathan Webster
Jul 4, 2020·American Journal of Hematology·Samer A SrourStefan O Ciurea
Dec 7, 2019·Hematology·Adam J Lamble, Sarah K Tasian
Aug 3, 2019·Science China. Life Sciences·Yu WangXiaojun Huang
Jul 1, 2020·Current Treatment Options in Oncology·Felicitas Thol, Arnold Ganser
Nov 27, 2019·Blood Advances·Adam J Lamble, Sarah K Tasian
Aug 25, 2020·American Journal of Hematology·Elihu H Estey
Sep 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ali BazarbachiMohamad Mohty
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph C RimandoJohn F DiPersio
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph SchmidGesine Bug
Jan 22, 2021·Haematologica·Andreas Burchert
Sep 24, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bhagirathbhai DholariaArnon Nagler
May 14, 2021·Blood·Christoph Schmid
Jun 8, 2021·HemaSphere·Felicitas Thol, Michael Heuser
Jul 27, 2021·Transplantation and Cellular Therapy·Usama Gergis, Dolores Grosso

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Blood
Christoph SchmidAcute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
© 2022 Meta ULC. All rights reserved